Skip to Main Content


Barbara Burtness, MD

Professor of Medicine (Medical Oncology); Interim Associate Cancer Center Director, Diversity, Equity, and Inclusion; Chief, Head and Neck Cancers/Sarcoma; Disease Aligned Research Team Leader, Head and Neck Cancers Program; Co-Leader, Developmental Therapeutics, Yale Cancer Center



Barbara Burtness, MD is Professor of Medicine (Medical Oncology) at the Yale School of Medicine and Interim Associate Director for Diversity, Equity and Inclusion at the Yale Cancer Center. She serves as Co-Leader of the Developmental Therapeutics Program, Leader of the Disease Aligned Research for Head and Neck Cancer, and Director of the Yale Head and Neck Specialized Program of Research Excellence. Dr. Burtness is internationally recognized for her research in head and neck cancer. She chairs the ECOG-ACRIN Cooperative Group Head and Neck Cancer Therapeutics Committee, and leads national and international trials of targeted therapy in head and neck cancer. Her laboratory studies synthetic lethal therapeutic strategies in head and neck cancer and the targeting of aurora kinase A to overcome adaptive resistance to EGFR inhibition and - in lung cancer- to direct KRAS inhibition.

Education & Training

  • Fellowship
    Memorial Sloan Kettering Cancer Center (1993)
  • Residency
    Yale-New Haven Hospital (1989)
  • Internship
    Yale-New Haven Hospital (1987)
  • MD
    SUNY at Stonybrook (1986)
  • AB
    Bryn Mawr College (1982)

Honors & Recognition

AwardAwarding OrganizationDate
Robert L. Krigel Award, Excellence in Teaching and Clinical OncologyFox Chase Cancer Center2012
Top DoctorU.S. News and World Report
Best Doctors in AmericaBest Doctors

Professional Service

ECOG-ACRINChair of the ECOG-ACRIN Head and Neck Therapeutics Committee2006 - Present

Departments & Organizations